Table 3.
NHL risk and exposure to organochlorines, stratified by genotype for selected single nucleotide polymorphisms (SNPs)
| SNP genotype | PCB180 in plasma, pg/g lipid |
PCB180 in carpet dust, ng/g |
TEQ in plasma, pg/g lipid |
α-Chlordane in carpet dust, ng/g |
Termite treatment before 1988 |
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ca/Co* | NHL risk (95% CI), %† | P | P for inter-action | Ca/Co* | NHL risk (95% CI), %† | P | P for inter-action | Ca/Co* | NHL Risk (95 CI), %† | P | P for inter-action | Ca/Co* | NHL risk (95 CI), %† | P | P for inter-action | Ca/Co* | OR (95 CI)‡ | P for inter-action | ||
| IFNG C−1615T | .12 | .48 | .30 | .099 | .29 | |||||||||||||||
| TT | 39/46 | 16.9 (3.7-31.6) | .010 | 243/188 | 1.2 (0.1-2.4) | .033 | 39/45 | 19.2 (4.8-35.7) | .008 | 243/188 | 1.1 (0.1-2.1) | .030 | 379/319 | 1.5 (1.0-2.3) | ||||||
| CT/CC | 53/50 | 3.8 (−4.0-12.2) | .35 | 333/245 | 0.5 (−0.5-1.4) | .34 | 50/46 | 2.6 (−5.4-11.3) | .53 | 333/245 | 0.1 (−0.7-0.9) | .77 | 508/421 | 1.1 (0.7-1.5) | ||||||
| IL4 5′-UTR, Ex1−168C>T | .21 | .21 | .021 | .50 | .85 | |||||||||||||||
| CC | 62/64 | 9.3 (0.9-18.3) | .030 | 403/294 | 1.0 (0.1-1.9) | .027 | 60/61 | 12.5 (3.0-22.9) | .009 | 403/294 | 0.6 (−0.2-1.4) | .14 | 634/490 | 1.3 (1.0-1.9) | ||||||
| CT/TT | 30/29 | 3.0 (−7.9-15.1) | .61 | 192/159 | 0.1 (−1.1-1.4) | .84 | 29/27 | 0.4 (−13.2-16.1) | .96 | 192/159 | 0.3 (−0.7-1.4) | .57 | 287/275 | 1.0 (0.6-1.5) | ||||||
| IL16 3′-UTR, Ex22+871A>G | .002 | .11 | .66 | .77 | .24 | |||||||||||||||
| AA | 46/48 | 15 (3.2-28.0) | .011 | 330/230 | 1.1 (0.1-2.1) | .029 | 44/44 | 11.2 (−0.3-24.0) | .057 | 330/230 | 0.5 (−0.3-1.4 | .25 | 478/376 | 1.2 (0.8-1.7) | ||||||
| AG/GG | 45/45 | 0.5 (−8.5-10.4) | .91 | 254/218 | 0.2 (−0.9-1.2) | .76 | 44/44 | 10.3 (−1.3-23.4) | .085 | 254/218 | 0.5 (−0.5-1.4) | .33 | 424/376 | 1.1 (0.8-1.7) | ||||||
| IL8 T−251A | .063 | .36 | .80 | .28 | .98 | |||||||||||||||
| TT | 27/29 | 28.9 (6.4-56.1) | .010 | 172/131 | 1.4 (0.05-2.8) | .043 | 27/28 | 8.8 (−4.4-23.9) | .20 | 172/131 | 0.3 (−0.8-1.5) | .60 | 246/216 | 1.3 (0.8-2.2) | ||||||
| AT/AA | 64/67 | 4.8 (−2.2-12.3) | .19 | 401/300 | 0.5 (−0.4-1.4) | .27 | 61/63 | 9.1 (0.4-18.6) | .041 | 401/300 | 0.6 (−0.2-1.4) | .12 | 637/522 | 1.2 (0.9-1.7) | ||||||
| IL10 A−1082G | .14 | .37 | .97 | .53 | .67 | |||||||||||||||
| AA | 31/28 | 6.6 (−5.1-19.7) | .28 | 168/144 | 0.5 (−0.8-1.8) | .44 | 30/25 | 15.8 (−1.5-36.0) | .075 | 168/144 | 0.2 (−0.9-1.4) | .71 | 266/239 | 1.1 (0.6-1.7) | ||||||
| AG/GG | 59/66 | 9.9 (1.2-19.4) | .025 | 431/309 | 0.9 (0.05-1.8) | .038 | 57/64 | 5.0 (−3.0-13.8) | .23 | 431/309 | 0.6 (−0.2-1.3) | .13 | 651/530 | 1.2 (0.9-1.7) | ||||||
NHL indicates non-Hodgkin lymphoma; OR, odds ratio; CI, confidence interval; PCB, polychlorinated biphenyl; and TEQ, toxic equivalency quotient.
*
Number of cases and controls included in the risk analysis for that genotype.
†
Increase in NHL risk for each 10% increase in exposure level.
‡
Referents were participants whose homes were never treated for termites or were treated only after 1988.